Saijuan Shengwu
Overview
国内干细胞新药研发领域领军企业；专注于干细胞创新药物的研发、临床转化与产业化；华南地区干细胞药物临床批件数量最多、临床研发进展最迅速.
Funding and backers
Latest round
Series B
Mar 2026 · 7 mo ago
Team
51-200
employees, estimated range
The money's age
Fresh money
7 months since the last round · not hiring
Momentum
20/100
fresh money
The story so fareach stage dated by its source: the company's releases, the press, registers, filings
Funding rounds
| Round | Date | Amount | Investors | Source |
|---|---|---|---|---|
| Series B | Mar 2026 | — | — | 投资界 |
Financials
Latest round
Series B
Funding rounds
1
Investors
1
Funding rounds
| Round | Announced | Amount | |
|---|---|---|---|
| Series B | 2026 | — | Details |
Key Investors
广州市达安医疗健康产业创业投资基金（有限合伙）
shareholder on the register (清科 zdb)
Offices
Where the company hires and what each office is for
Cities
1
Hiring now
0
Countries
1
Guangzhou
China
HQ
50-200 est. staff